MOR103, a human monoclonal antibody to granulocyte–macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial

@inproceedings{Behrens2015MOR103AH,
  title={MOR103, a human monoclonal antibody to granulocyte–macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial},
  author={F. H. Behrens and Paul Peter Tak and Mikkel \Ostergaard and Rumen M. Stoilov and Piotr Wiland and Thomas W. J. Huizinga and Vadym Y Berenfus and Stoyanka Vladeva and J{\"u}rgen Rech and Andrea Rubbert-Roth and Mariusz Korkosz and Dmitriy Rekalov and Igor A Zupanets and Bo Jannik Ejbjerg and Jens Geiseler and Julia Fresenius and Roman Paweł Korolkiewicz and Arndt J G Schottelius and Harald Burkhardt},
  booktitle={Annals of the rheumatic diseases},
  year={2015}
}
OBJECTIVES To determine the safety, tolerability and signs of efficacy of MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF), in patients with rheumatoid arthritis (RA). METHODS Patients with active, moderate RA were enrolled in a randomised, multicentre, double-blind, placebo-controlled, dose-escalation trial of intravenous MOR103 (0.3, 1.0 or 1.5 mg/kg) once a week for 4 weeks, with follow-up to 16 weeks. The primary outcome was safety… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
Blog posts, news articles and tweet counts and IDs sourced by
Altmetric.com